GLP1R and coronary artery disorder: In 10 patients with CAD undergoing PCI of the LAD, glucagon-like peptide-1 (GLP-1) increased invasively measured resting coronary flow velocity and decreased basal microcirculatory resistance compared with placebo, although GLP-1 did not affect hyperemic pressure or flow velocity indexes.71